10x Genomics Shares Tumble on Fear Over Cuts to NIH
A Wednesday night earnings report left big questions about how the spending reductions would affect the company.
10x Genomics (NASDAQ:TXG) Given New $18.00 Price Target at Stifel Nicolaus
Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...
StockStory.org on MSN2d
Why 10x Genomics (TXG) Shares Are Falling Today
Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported ...
10x Genomics (TXG) Receives a Buy from Morgan Stanley
Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...
Fintel on MSN1d
Leerink Partners Downgrades 10x Genomics (TXG)
Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...
10x Genomics price target lowered to $18 from $21 at Stifel
Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment ...
StockStory.org on MSN2d
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations
Detailed price information for 10X Genomics Inc (TXG-Q) from The Globe and Mail including charting and trades.
Zacks.com on MSN2d
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
Genomics (TXG) delivered earnings and revenue surprises of -25% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?